Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
Provided By GlobeNewswire
Last update: May 13, 2025
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Read more at globenewswire.comNASDAQ:FBIO (12/17/2025, 11:12:54 AM)
3.64
+0.13 (+3.7%)
Find more stocks in the Stock Screener
